Influence of serum cumulative triglyceride exposure on the risk of acute pancreatitis

Afang SU; Xiaozhong JIANG; Yunshui ZHANG; Shouling WU; Guangjian LI

doi:10.12449/JCH241220

Volume 40 Issue 12

Dec. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(12): 2492-2498

PDF( 770 KB)

Influence of serum cumulative triglyceride exposure on the risk of acute pancreatitis

DOI: 10.12449/JCH241220

1a.
Department of Gastroenterology，Kailuan General Hospital，Tangshan，Hebei 063000，China
1b.
Department of Cardiology，Kailuan General Hospital，Tangshan，Hebei 063000，China
2.
Department of Critical Care Medicine，Air Force Medical Center，Air Force Medical University，Beijing 100142，China

Research funding:

Special Research Fund of Hebei Health Planning Commission (20221582)

Received Date: 2024-04-23
Accepted Date: 2024-07-08
Published Date: 2024-12-25

Abstract

Abstract

Objective To investigate the association between cumulative triglyceride （cumTG） exposure and the risk of acute pancreatitis （AP）. Methods A prospective study was conducted for a cohort of 56 883 workers from Kailuan Group who participated in annual physical examination for three consecutive times in 2006-2010 （2006， 2008， and 2010） and had complete TG data without the medical history of AP. According to the quartiles of cumTG calculated， the subjects were divided into four groups （Q1， Q2， Q3， and Q4 groups）， and general information was compared between the two groups. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups， and the Kruskal-Wallis H test was used for comparison of continuous data with skewed distribution between multiple groups； the chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used to plot the survival curve and calculate the cumulative incidence rate of AP， and the Log-rank test was used for comparison between groups； the Cox regression model was used to analyze the effect of different cumTG levels on new-onset AP events. Results After follow-up for 10.51±1.76 years， there were 158 AP events in total， with a total incidence density of 2.64 per 10 000 person-years， and the number of cases and incidence density in the Q1， Q2， Q3， and Q4 groups were 29 cases （1.93 per 10 000 person-years）， 34 cases （2.27 per 10 000 person-years）， 30 cases （2.01 per 10 000 person-years）， and 65 cases （4.37 per 10 000 person-years）. The Log-rank test showed that there was a significant difference in cumulative incidence rate between groups （χ²=22.41， P<0.001）. The multivariate Cox regression analysis showed that compared with the Q1 group， the Q4 group had a significantly higher risk of AP （hazard ratio ［HR］=1.94， 95% confidence interval ［CI］： 1.20‍ ‍—‍ 3.13， P=0.01）. Compared with cumulative triglyceride exposure for 0 year， cumulative triglyceride exposure for 4 and 6 years significantly increased the risk of AP， with an HR value of 2.04 （95%CI： 1.26‍ ‍—‍ 3.30， P<0.01） and 3.20 （95%CI： 1.98‍ ‍—‍ 5.17， P<0.01）， respectively. After exclusion of the AP cases that occurred during the 2-year follow-up， the repeated multivariate Cox regression analysis showed that the Q4 group had an HR value of 1.96 （95%CI： 1.23‍ ‍—‍ 3.12， P<0.01） for the onset of AP， and after exclusion of the death cases during follow-up， the repeated multivariate Cox regression analysis showed that the Q4 group had an HR value of 1.85 （95%CI： 1.10‍ ‍—‍ 3.14， P<0.05） for the onset of AP. Conclusion The incidence rate and risk of AP tend to increase with the increase in cumTG exposure.
- Triglycerides,
- Acute Pancreatitis,
- Risk Factors

FullText(HTML)

References(30)

References

[1]	ROBERTS SE, MORRISON-REES S, JOHN A, et al. The incidence and aetiology of acute pancreatitis across Europe[J]. Pancreatology, 2017, 17( 2): 155- 165. DOI: 10.1016/j.pan.2017.01.005.
[2]	LIN HH, CHANG HY, CHIANG YT, et al. Smoking, drinking, and pancreatitis: A population-based cohort study in Taiwan[J]. Pancreas, 2014, 43( 7): 1117- 1122. DOI: 10.1097/MPA.0000000000000209.
[3]	GRAJALES-FIGUEROA G, DÍAZ HERNÁNDEZ HA, CHACÓN PORTILLO MA, et al. Increased mortality from extrapancreatic infections in hospitalized patients with acute pancreatitis[J]. Gastroenterol Res Pract, 2019, 2019: 2789764. DOI: 10.1155/2019/2789764.
[4]	JIN JL, SUN D, CAO YX, et al. Intensive genetic analysis for Chinese patients with very high triglyceride levels: Relations of mutations to triglyceride levels and acute pancreatitis[J]. EBioMedicine, 2018, 38: 171- 177. DOI: 10.1016/j.ebiom.2018.11.001.
[5]	REID GP, WILLIAMS EW, FRANCIS DK, et al. Acute pancreatitis: A 7 year retrospective cohort study of the epidemiology, aetiology and outcome from a tertiary hospital in Jamaica[J]. Ann Med Surg(Lond), 2017, 20: 103- 108. DOI: 10.1016/j.amsu.2017.07.014.
[6]	HONG WD, ZIMMER V, BASHARAT Z, et al. Association of total cholesterol with severe acute pancreatitis: A U-shaped relationship[J]. Clin Nutr, 2020, 39( 1): 250- 257. DOI: 10.1016/j.clnu.2019.01.022.
[7]	Expert group of emergency expert consensus on diagnosis and treatment of hypertriglyceridemic acute pancreatitis. Emergency expert consensus on diagnosis and treatment of hypertriglyceridemic acute pancreatitis[J]. Chin Gen Pract, 2021, 24( 30): 3781- 3793. DOI: 10.12114/j.issn.1007-9572.2021.02.028. 《高甘油三酯血症性急性胰腺炎诊治急诊专家共识》专家组. 高甘油三酯血症性急性胰腺炎诊治急诊专家共识[J]. 中国全科医学, 2021, 24( 30): 3781- 3793. DOI: 10.12114/j.issn.1007-9572.2021.02.028.
[8]	TENNER S, BAILLIE J, DEWITT J, et al. American college of gastroenterology guideline: Management of acute pancreatitis[J]. Am J Gastroenterol, 2013, 108( 9): 1400- 1415. DOI: 10.1038/ajg.2013.218.
[9]	BERGLUND L, BRUNZELL JD, GOLDBERG AC, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2012, 97( 9): 2969- 2989. DOI: 10.1210/jc.2011-3213.
[10]	JI RG, ZHU GL, ZHANG B, et al. Association between dyslipidemia and acute pancreatitis: A prospective cohort study[J]. J Clin Hepatol, 2019, 35( 7): 1536- 1540. DOI: 10.3969/j.issn.1001-5256.2019.07.023. 吉瑞更, 朱国玲, 张冰, 等. 血脂异常对急性胰腺炎发病影响的前瞻性队列研究[J]. 临床肝胆病杂志, 2019, 35( 7): 1536- 1540. DOI: 10.3969/j.issn.1001-5256.2019.07.023.
[11]	WANG GD, SONG L, ZHAO HL, et al. Predictive value of cumulative blood pressure exposure to stroke events[J]. Chin J Hypertens, 2017, 25( 8): 773- 778. DOI: 10.16439/j.cnki.1673-7245.2017.08.026. 汪国栋, 宋路, 赵华灵, 等. 累积血压暴露值对脑卒中事件的预测价值[J]. 中华高血压杂志, 2017, 25( 8): 773- 778. DOI: 10.16439/j.cnki.1673-7245.2017.08.026.
[12]	WANG JR, HU YQ, SHI HJ, et al. Study on the assiociation between cumulative uric acid and brachial-ankle pulse velocity[J]. Chin J Rheumatol, 2019, 4( 23): 220- 227. DOI: 10.3760/cma.j.issn.1007-7480.2019.04.002. 王洁蕊, 胡玉琴, 石慧婧, 等. 累积尿酸暴露与臂踝动脉脉搏波传导速度的关系[J]. 中华风湿病学杂志, 2019, 4( 23): 220- 227. DOI: 10.3760/cma.j.issn.1007-7480.2019.04.002.
[13]	WU SL, HUANG ZR, YANG XC, et al. Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city[J]. Circ Cardiovasc Qual Outcomes, 2012, 5( 4): 487- 493. DOI: 10.1161/CIRCOUTCOMES.111.963694.
[14]	ZHU GL, CHEN SH, FAN XD, et al. A prospective cohort study on BMI levels and risk of acute pancreatitis[J]. Chin J Epidemiol, 2021, 42( 12): 2131- 2137. DOI: 10.3760/cma.j.cn112338-20201027-01286. 朱国玲, 陈朔华, 樊学东, 等. 基线BMI水平对急性胰腺炎发病风险影响的前瞻性队列研究[J]. 中华流行病学杂志, 2021, 42( 12): 2131- 2137. DOI: 10.3760/cma.j.cn112338-20201027-01286.
[15]	ZHANG B, ZHU GL, SUN Q, et al. Baseline fasting glucose and risk of acute pancreatitis: A prospective cohort study[J]. Chin Gen Pract, 2021, 24( 1): 60- 64. DOI: 10.12114/j.issn.1007-9572.2020.00.602. 张冰, 朱国玲, 孙秋, 等. 基线空腹血糖水平与急性胰腺炎发病风险的前瞻性队列研究[J]. 中国全科医学, 2021, 24( 1): 60- 64. DOI: 10.12114/j.issn.1007-9572.2020.00.602.
[16]	Writing Group of 2018 Chinese Guidelines for the Management of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology, et al. Chinese guidelines for the management of hypertension(2018 revised edition)[J]. Chin J Cardiovasc Med, 2019, 24( 1): 24- 56. DOI: 10.3969/j.issn.1007-5410.2019.01.002. 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24( 1): 24- 56. DOI: 10.3969/j.issn.1007-5410.2019.01.002.
[17]	Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China(2017 Edition)[J]. Chin J Pract Intern Med, 2018, 38( 4): 292- 344. DOI: 10.19538/j.nk2018040108. 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38( 4): 292- 344. DOI: 10.19538/j.nk2018040108.
[18]	Pancreas Study Group, Chinese Society of Gastroenterology, Chinese Medical Association; Editorial Board of Chinese Journal of Pancreatology; Editorial Board of Chinese Journal of Digestion. Chinese guidelines for the management of acute pancreatitis(Shenyang, 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2706- 2711. DOI: 10.3969/j.issn.1001-5256.2019.12.013. 中华医学会消化病学分会胰腺疾病学组,《中华胰腺病杂志》编委会,《中华消化杂志》编委会. 中国急性胰腺炎诊治指南(2019年, 沈阳)[J]. 临床肝胆病杂志, 2019, 35( 12): 2706- 2711. DOI: 10.3969/j.issn.1001-5256.2019.12.013.
[19]	SU W, GUO F. Triglyceride-controlling during acute phase of hypertriglyceridemia induced pancreatitis[J]. Chin J Dig Surg, 2023, 22( 1): 89- 93. DOI: 10.3760/cma.j.cn115610-20221220-00755. 苏伟, 郭丰. 高甘油三酯血症性胰腺炎急性期的血脂控制[J]. 中华消化外科杂志, 2023, 22( 1): 89- 93. DOI: 10.3760/cma.j.cn115610-20221220-00755.
[20]	WU YQ, ZHAO JC. Predictive value of Ranson score in the classification of moderate to severe hyperlipidemia acute pancreatitis[J]. J Clin Exp Med, 2022, 21( 2): 222- 225. DOI: 10.3969/j.issn.1671-4695.2022.02.029. 吴永强, 赵景成. Ranson评分在高脂血症性急性胰腺炎病情严重程度评估中的应用价值[J]. 临床和实验医学杂志, 2022, 21( 2): 222- 225. DOI: 10.3969/j.issn.1671-4695.2022.02.029.
[21]	Joint committee for guideline revision. 2016 Chinese guidelines for the management of dyslipidemia in adults[J]. J Geriatr Cardiol, 2018, 15( 1): 1- 29. DOI: 10.11909/j.issn.1671-5411.2018.01.011.
[22]	ZHU GL, ZHANG B, JI RG, et al. A prospective cohort study on triglycerides levels and risk of acute pancreatitis[J]. Chin J Dig, 2018, 38( 12): 829- 834. DOI: 10.3760/cma.j.issn.0254-1432.2018.12.008. 朱国玲, 张冰, 吉瑞更, 等. 基线三酰甘油水平与急性胰腺炎发病风险的前瞻性队列研究[J]. 中华消化杂志, 2018, 38( 12): 829- 834. DOI: 10.3760/cma.j.issn.0254-1432.2018.12.008.
[23]	LINDKVIST B, APPELROS S, REGNÉR S, et al. A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose[J]. Pancreatology, 2012, 12( 4): 317- 324. DOI: 10.1016/j.pan.2012.05.002.
[24]	PEDERSEN SB, LANGSTED A, NORDESTGAARD BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis[J]. JAMA Intern Med, 2016, 176( 12): 1834- 1842. DOI: 10.1001/jamainternmed.2016.6875.
[25]	EWALD N, HARDT PD, KLOER HU. Severe hypertriglyceridemia and pancreatitis: Presentation and management[J]. Curr Opin Lipidol, 2009, 20( 6): 497- 504. DOI: 10.1097/MOL.0b013e3283319a1d.
[26]	GERASIMENKO JV, GERASIMENKO OV, PETERSEN OH. The role of Ca²⁺ in the pathophysiology of pancreatitis[J]. J Physiol, 2014, 592( 2): 269- 280. DOI: 10.1113/jphysiol.2013.261784.
[27]	ZHANG XL, LI F, CUI YQ, et al. The role of oxide stress during the pathogenesis of chronic pancreatic injuries induced by chronic high-fat diets in rat[J]. Chin J Surg, 2012, 50( 7): 646- 649. DOI: 10.3760/cma.j.issn.0529-5815.2012.07.019. 张小丽, 李非, 崔叶青, 等. 氧应激在慢性胰腺损伤发生中的表达变化[J]. 中华外科杂志, 2012, 50( 7): 646- 649. DOI: 10.3760/cma.j.issn.0529-5815.2012.07.019.
[28]	VALDIVIELSO P, RAMIREZ-BUENO A, EWALD N. Current knowledge of hypertriglyceridemic pancreatitis[J]. Eur J Intern Med, 2014, 25( 8): 689- 694. DOI: 10.1016/j.ejim.2014.08.008.
[29]	RAWLA P, SUNKARA T, THANDRA KC, et al. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies[J]. Clin J Gastroenterol, 2018, 11( 6): 441- 448. DOI: 10.1007/s12328-018-0881-1.
[30]	Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guidelines for lipid management(2023)[J]. Chin J Cardiol, 2023, 51( 3): 221- 255. DOI: 10.3760/cma.j.cn112148-20230119-00038. 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51( 3): 221- 255. DOI: 10.3760/cma.j.cn112148-20230119-00038.

Relative Articles

[1]	Shiwan ZHANG, Xing CHEN, Jiao LIU, Min ZHAO, Xiaoping MEI. Expression levels of HBV pregenomic RNA and hepatitis B core-related antigen in circulating serum and their association with recurrence in chronic hepatitis B patients after withdrawal from nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2023, 39(1): 56-62. doi: 10.3969/j.issn.1001-5256.2023.01.009
[2]	Fengping WU, Miaoxian LI, Yikai WANG, Rui LU, Yixin LIU, Shuangsuo DANG. Dynamic changes of HBsAg and hepatitis B virus DNA in chronic hepatitis B patients with entecavir monotherapy for 5 years[J]. Journal of Clinical Hepatology, 2021, 37(5): 1047-1052. doi: 10.3969/j.issn.1001-5256.2021.05.015
[3]	Sun Jing, Zhu Lin, Chi Xin, Wang YiXuan, Xing HuiChun. Effect of entecavir antiviral therapy alone or combined with interferon on the risk of hepatocellular carcinoma in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(9): 1975-1979. doi: 10.3969/j.issn.1001-5256.2020.09.013
[4]	Zai WenJing, Chen JieLiang, Yuan ZhengHong. Regulatory mechanisms of the transcription and metabolism of hepatitis B virus covalently closed circular DNA and strategies for silencing and elimination[J]. Journal of Clinical Hepatology, 2020, 36(5): 983-988. doi: 10.3969/j.issn.1001-5256.2020.05.006
[5]	Zhang Qing, Zhang Biao, Wang Pei, Li Ying, Yan XueBing, Ding Qin. Influence of long-term entecavir treatment on renal function in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(7): 1491-1495. doi: 10.3969/j.issn.1001-5256.2020.07.010
[6]	Liao Hao, Wang Jie, Lu FengMin. Application value of serum HBV RNA in clinical management of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2019, 35(10): 2145-2149. doi: 10.3969/j.issn.1001-5256.2019.10.003
[7]	Zhou YouQian, Li Cui, Yin FengMing, Zhang HaiYan, Ren Bin, Yang Wei. Change in HBsAg quantification after HBV DNA negative conversion in chronic hepatitis B patients treated with nucleos (t) ide analogues[J]. Journal of Clinical Hepatology, 2019, 35(5): 977-981. doi: 10.3969/j.issn.1001-5256.2019.05.009
[8]	Zhang Yu, Zhao JingMin. Clinical application of covalently closed circular DNA detection techniques[J]. Journal of Clinical Hepatology, 2019, 35(10): 2140-2144. doi: 10.3969/j.issn.1001-5256.2019.10.002
[9]	Zhang JiaWei, Geng JiaBao, Lu Feng, Dong Yu. Clinical effect of tenofovir disoproxil fumarate versus entecavir in treatment of treatment-naïve patients with chronic HBV infection[J]. Journal of Clinical Hepatology, 2018, 34(2): 272-275. doi: 10.3969/j.issn.1001-5256.2018.02.011
[10]	Wang HaiXia, Qi Yue. ‍Changes in serological markers of HBV during 4-year antiviral treatment with entecavir: A case report[J]. Journal of Clinical Hepatology, 2018, 34(12): 2648-2649. doi: 10.3969/j.issn.1001-5256.2018.12.027
[11]	Ji HuiChun, Zhang ZhenJiang, Zhu Fang, Liu JunQuan, Liu QingDe, Pang Wei. Clinical effect of alprostadil combined with entecavir in treatment of HBV-related liver failure complicated by ascites[J]. Journal of Clinical Hepatology, 2016, 32(11): 2151-2154. doi: 10.3969/j.issn.1001-5256.2016.11.030
[12]	Hong YouZhi, Huang JiShui, Hong WenCong, Jiang TaoYuan. Clinical effect of entecavir combined with antituberculosis therapy in patients with tuberculosis complicated by chronic HBV infection[J]. Journal of Clinical Hepatology, 2016, 32(11): 2088-2091. doi: 10.3969/j.issn.1001-5256.2016.11.015
[13]	Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Research advances in therapeutic strategies against covalently closed circular DNA of hepatitis B virus[J]. Journal of Clinical Hepatology, 2015, 31(9): 1520-1523. doi: 10.3969/j.issn.1001-5256.2015.09.040
[14]	Cai ShaoPing, Liu Ze, Xu DongPing. Significance and progress in detection of HBV cccDNA in peripheral blood mononuclear cells[J]. Journal of Clinical Hepatology, 2014, 30(8): 819-821. doi: 10.3969/j.issn.1001-5256.2014.08.034
[15]	Chen Wei, Wu Feng, Dou XiaoGuang, Zhang Lin. Analysis of related factors for intrahepatic HBV cccDNA level in patients with chronic HBV infection[J]. Journal of Clinical Hepatology, 2013, 29(6): 434-437.
[16]	Zhao Pan, Zhong YanWei, Xu DongPing. A181 site mutation in HBV reverse transcriptase region on chronic HBV-infected patients during Entecavir therapy[J]. Journal of Clinical Hepatology, 2011, 27(3): 289-291.
[17]	Xu ChunHai, Li ZhaoShen, Dai JunYing, Zhu HaiYang, Yu JianWu, Lu: ShuLan. Establishment and application of nested real-time fluorescent quantitative polymerase chain reaction assay for detection of hepatitis B virus covalently closed circular DNA[J]. Journal of Clinical Hepatology, 2011, 27(3): 283-285+291.
[19]	Kan Xiao, Shi ZhaoZhang, Zheng ZhaoMin, Han ShaoLei. The effect of Entikawei in the treatment of hopatitis B virus associated glomerulonephritis (HBV-GN)[J]. Journal of Clinical Hepatology, 2008, 24(6): 426-427.
[20]	Zhang LeiJia, Zhang JinPing, Hu Bing. Relationship between Cytokines in children and HBV DNA in serum, hepatitis B virus markers.[J]. Journal of Clinical Hepatology, 2006, 22(1): 27-28.

Supplements(0)

Cited By

Cited by

Periodical cited type(17)

1.	王学英. HBV pgRNA联合cccDNA对慢性乙型肝炎患者抗病毒疗效的预测价值. 罕少疾病杂志. 2024(04): 54-56 .
2.	周芳，王永平，欧阳宇. HBV pgRNA联合HBcrAg对慢性乙型肝炎患者停药后复发的预测价值. 中国肝脏病杂志(电子版). 2024(02): 42-47 .
3.	徐国球，李平生，吴细妹. 乙型肝炎病毒前基因组RNA评估恩替卡韦治疗乙型肝炎E抗原阳性慢性乙型肝炎疗效的价值. 大医生. 2023(01): 111-113 .
4.	张小花. HBV-DNA、HBsAg联合肝纤维化四项定量检测对鉴别乙型肝炎肝硬化的临床意义. 吉林医学. 2023(03): 620-622 .
5.	张华敏，刘娜，邓巧娟，张春梅. HBV感染相关性肝癌患者血清HBcrAg检测的临床价值分析. 中外医疗. 2023(07): 117-121 .
6.	乔梁. 慢性乙型肝炎患者外周血IL-17、IL-23水平与HBV-DNA的关系. 淮海医药. 2023(04): 361-364 .
7.	严景全，王春玲，刘娟，卢雪兰，林占洲，莫凡. 血清乙型肝炎病毒前基因组RNA水平对核苷(酸)类似物初治的慢性乙型肝炎患者疗效预测价值. 实用肝脏病杂志. 2022(01): 22-25 .
8.	卢艳玲，李小红，陈海涛. 慢性乙型肝炎患者血清HBV pgRNA与HBV DNA和HBeAg水平变化关系研究. 肝脏. 2022(03): 302-304 .
9.	杜思思，柳侠平. 自拟胁通膏穴位贴敷治疗慢性乙型肝炎的疗效观察. 中国中医药科技. 2022(05): 807-809 .
10.	王春莹，屈耀宁，乔炜，刘静静，胡颖辉. 恩替卡韦治疗慢性乙型肝炎患者血清HBV cccDNA和HBV pgRNA水平变化. 实用肝脏病杂志. 2022(05): 641-644 .
11.	卢北玲，史剑飞，董远峰，王蕊，宋晶晶，彭晶. 慢性乙型肝炎与乙肝肝硬化HBV RNA和HBV DNA的差异及相关性分析. 延安大学学报(医学科学版). 2022(03): 38-41 .
12.	于彤波，付伦，赵汉东，王嘉，刘红莉. 血清HBV pgRNA在核苷类似物治疗CHB患者中的临床价值. 检验医学与临床. 2022(21): 2881-2884+2889 .
13.	梁惠娟，郑珉敏，杨小川. 替诺福韦与恩替卡韦治疗慢性乙型肝炎的临床疗效观察及不良反应分析. 中国处方药. 2021(05): 95-97 .
14.	李解军，冯煦，常瑞霞. HBsAg、cccDNA和pgRNA水平检测在慢性乙型肝炎诊治中的价值. 保健医学研究与实践. 2021(04): 95-98+102 .
15.	黄丽帆. 恩替卡韦预防性治疗对HBV合并肺结核患者肝损伤的保护效果. 中外医学研究. 2021(26): 161-164 .
16.	李娟，曹平虎，唐先梅，何旭，王婷. 双环醇片联合恩替卡韦治疗慢性乙型肝炎疗效及对患者肝功能的保护作用. 陕西医学杂志. 2021(10): 1271-1274 .
17.	王成康，刘寿荣. 慢性乙型病毒性肝炎患者抗病毒治疗的生物标志物进展. 中西医结合肝病杂志. 2021(06): 574-576 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (279) PDF downloads(30)